{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T02:24:59Z","timestamp":1792981499931,"version":"4.5.0"},"reference-count":118,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000923","name":"Australian Research Council","doi-asserted-by":"publisher","award":["DP230100485"],"award-info":[{"award-number":["DP230100485"]}],"id":[{"id":"10.13039\/501100000923","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015539","name":"Commonwealth of Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015539","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Theoretical Biology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jtbi.2026.112493","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T09:17:28Z","timestamp":1778577448000},"page":"112493","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Optimisation of pembrolizumab therapy for de novo metastatic MSI-H\/dMMR colorectal cancer using data-driven delay integro-differential equations"],"prefix":"10.1016","volume":"629","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-6093-8769","authenticated-orcid":false,"given":"Georgio","family":"Hawi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1492-4744","authenticated-orcid":false,"given":"Peter S.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2660-4377","authenticated-orcid":false,"given":"Peter P.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtbi.2026.112493_bib0001","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/psp4.12139","article-title":"Model-based characterization of the pharmacokinetics of pembrolizumab: a humanized anti-PD-1 monoclonal antibody in advanced solid tumors","volume":"6","author":"Ahamadi","year":"2016","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"10.1016\/j.jtbi.2026.112493_bib0002","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1200\/JCO.2018.36.4_suppl.553","article-title":"Nivolumab + ipilimumab combination in patients with DNA mismatch repair-deficient\/microsatellite instability-high (dMMR\/MSI-H) metastatic colorectal cancer (mCRC): first report of the full cohort from CheckMate-142","volume":"36","author":"Andre","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jtbi.2026.112493_bib0003","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability\u2013High advanced colorectal cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jtbi.2026.112493_bib0004","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1007\/s11606-018-4648-7","article-title":"Risk factors for diagnosis of colorectal cancer at a late stage: a population-based study","volume":"33","author":"Andrew","year":"2018","journal-title":"J. Gen. Intern. Med."},{"key":"10.1016\/j.jtbi.2026.112493_bib0005","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1089\/jir.2012.0087","article-title":"Interferon-\u03b3-induced necrosis: an antitumor biotherapeutic perspective","volume":"33","author":"Balachandran","year":"2013","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.jtbi.2026.112493_bib0006","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.lungcan.2018.01.022","article-title":"Spatial interaction of tumor cells and regulatory T cells correlates with survival in non-small cell lung cancer","volume":"117","author":"Barua","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtbi.2026.112493_bib0007","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.cmpb.2007.07.002","article-title":"DAISY: A new software tool to test global identifiability of biological and physiological systems","volume":"88","author":"Bellu","year":"2007","journal-title":"Comput. Methods Programs Biomed."},{"key":"10.1016\/j.jtbi.2026.112493_bib0008","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-015-0455-8","article-title":"Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis","volume":"13","author":"Bertrand","year":"2015","journal-title":"BMC Med."},{"key":"10.1016\/j.jtbi.2026.112493_bib0009","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1001\/jama.2021.0106","article-title":"Diagnosis and treatment of metastatic colorectal cancer: a review","volume":"325","author":"Biller","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.jtbi.2026.112493_bib0010","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/s41577-019-0221-9","article-title":"Defining \u2018T cell exhaustion\u2019","volume":"19","author":"Blank","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jtbi.2026.112493_bib0011","first-page":"5248","article-title":"A national cancer institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer","volume":"58","author":"Boland","year":"1998","journal-title":"Cancer Res."},{"key":"10.1016\/j.jtbi.2026.112493_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.chaos.2023.113207","article-title":"A mathematical model with piecewise constant arguments of colorectal cancer with chemo-immunotherapy","volume":"168","author":"Bozkurt","year":"2023","journal-title":"Chaos Solit. Fractals"},{"key":"10.1016\/j.jtbi.2026.112493_bib0013","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.3390\/cancers13112632","article-title":"Data driven mathematical model of FOLFIRI treatment for colon cancer","volume":"13","author":"Budithi","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.jtbi.2026.112493_bib0014","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1038\/s41591-024-03083-7","article-title":"Botensilimab plus balstilimab in relapsed\/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial","volume":"30","author":"Bullock","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.jtbi.2026.112493_bib0015","doi-asserted-by":"crossref","first-page":"4680","DOI":"10.1158\/1078-0432.CCR-21-0557","article-title":"FDA approval summary: pembrolizumab for the first-line treatment of patients with MSI-H\/dMMR advanced unresectable or metastatic colorectal carcinoma","volume":"27","author":"Casak","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jtbi.2026.112493_bib0016","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.immuni.2004.08.007","article-title":"Visualizing the first 50 Hr of the primary immune response to a soluble antigen","volume":"21","author":"Catron","year":"2004","journal-title":"Immunity"},{"key":"10.1016\/j.jtbi.2026.112493_bib0017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/521957","article-title":"Functional and phenotypic plasticity of CD4+ T cell subsets","volume":"2015","author":"Caza","year":"2015","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.jtbi.2026.112493_bib0018","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s40262-019-00748-2","article-title":"Clinical pharmacokinetics and pharmacodynamics of immune checkpoint inhibitors","volume":"58","author":"Centanni","year":"2019","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jtbi.2026.112493_bib0019","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.molcel.2019.09.030","article-title":"Mechanisms controlling PD-L1 expression in cancer","volume":"76","author":"Cha","year":"2019","journal-title":"Mol. Cell"},{"key":"10.1016\/j.jtbi.2026.112493_bib0020","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1158\/2159-8290.CD-24-0190","article-title":"Botensilimab, an fc-enhanced anti\u2013CTLA-4 antibody, is effective against tumors poorly responsive to conventional immunotherapy","volume":"14","author":"Chand","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.jtbi.2026.112493_bib0021","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1093\/annonc\/mdw174","article-title":"Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer","volume":"27","author":"Chatterjee","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jtbi.2026.112493_bib0022","doi-asserted-by":"crossref","first-page":"11771","DOI":"10.1074\/jbc.M112.448126","article-title":"Structure and interactions of the human programmed cell death 1 receptor","volume":"288","author":"Cheng","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jtbi.2026.112493_bib0023","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.celrep.2014.06.052","article-title":"Antigen-specific inhibition of high-avidity t cell target lysis by low-avidity t cells via trogocytosis","volume":"8","author":"Chung","year":"2014","journal-title":"Cell Rep."},{"key":"10.1016\/j.jtbi.2026.112493_bib0024","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ctrv.2019.04.003","article-title":"Immunotherapy of colorectal cancer: challenges for therapeutic efficacy","volume":"76","author":"Ciardiello","year":"2019","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.jtbi.2026.112493_bib0025","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1245\/ASO.2005.06.012","article-title":"Surgical resection of primary tumors in patients who present with stage IV colorectal cancer: an analysis of surveillance, epidemiology, and end results data, 1988 to 2000","volume":"12","author":"Cook","year":"2005","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.jtbi.2026.112493_bib0026","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.01002","article-title":"TH9, TH17, and TH22 cell subsets and their main cytokine products in the pathogenesis of colorectal cancer","volume":"9","author":"Cui","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jtbi.2026.112493_bib0027","doi-asserted-by":"crossref","first-page":"3873","DOI":"10.1063\/1.1680571","article-title":"Study of the sensitivity of coupled reaction systems to uncertainties in rate coefficients. I theory","volume":"59","author":"Cukier","year":"1973","journal-title":"J. Chem. Phys."},{"key":"10.1016\/j.jtbi.2026.112493_bib0028","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.4049\/jimmunol.162.6.3256","article-title":"Inflammatory cytokines provide a third signal for activation of naive CD4+ and CD8+ T cells","volume":"162","author":"Curtsinger","year":"1999","journal-title":"J. Immunol."},{"key":"10.1016\/j.jtbi.2026.112493_bib0029","doi-asserted-by":"crossref","DOI":"10.1172\/JCI36628","article-title":"Tumor emergence is sensed by self-specific CD44hi memory tregs that create a dominant tolerogenic environment for tumors in mice","author":"Darrasse-J\u00e8ze","year":"2009","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.jtbi.2026.112493_bib0030","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s11538-006-9094-8","article-title":"Estimating lymphocyte division and death rates from CFSE data","volume":"68","author":"De Boer","year":"2006","journal-title":"Bull. Math. Biol."},{"key":"10.1016\/j.jtbi.2026.112493_bib0031","doi-asserted-by":"crossref","first-page":"4963","DOI":"10.4049\/jimmunol.170.10.4963","article-title":"Stochastic model of T cell proliferation: a calculus revealing IL-2 regulation of precursor frequencies, cell cycle time, and survival","volume":"170","author":"Deenick","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.jtbi.2026.112493_bib0032","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.9734\/BJMMR\/2014\/8393","article-title":"Mathematical model of colorectal cancer with monoclonal antibody treatments","volume":"4","author":"dePillis","year":"2014","journal-title":"Br. J. Med. Med. Res."},{"key":"10.1016\/j.jtbi.2026.112493_bib0033","doi-asserted-by":"crossref","DOI":"10.1186\/s40364-024-00640-7","article-title":"Oncological characteristics, treatments and prognostic outcomes in MMR-deficient colorectal cancer","volume":"12","author":"Fan","year":"2024","journal-title":"Biomark. Res."},{"key":"10.1016\/j.jtbi.2026.112493_bib0034","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.celrep.2016.03.075","article-title":"Genomic correlates of immune-cell infiltrates in colorectal carcinoma","volume":"15","author":"Giannakis","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.jtbi.2026.112493_bib0035","series-title":"Cell Surface Calreticulin: Role in Signaling Thrombospondin Anti-Adhesive Activity","first-page":"193","author":"Goicoechea","year":"2003"},{"key":"10.1016\/j.jtbi.2026.112493_bib0036","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.625423","article-title":"Roles of macrophages in the development and treatment of Gut inflammation","volume":"9","author":"Han","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.jtbi.2026.112493_bib0037","first-page":"727","article-title":"PD-1\/PD-L1 Pathway: current researches in cancer","volume":"10","author":"Han","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.jtbi.2026.112493_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtbi.2025.112231","article-title":"Optimisation of neoadjuvant pembrolizumab therapy for locally advanced MSI-H\/dMMR colorectal cancer using data-driven delay integro-differential equations","author":"Hawi","year":"2025","journal-title":"J. Theor. Biol."},{"key":"10.1016\/j.jtbi.2026.112493_bib0039","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/4772","article-title":"Directly measured kinetics of circulating t lymphocytes in normal and HIV-1-infected humans","volume":"5","author":"Hellerstein","year":"1999","journal-title":"Nat. Med."},{"key":"10.1016\/j.jtbi.2026.112493_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.jim.2020.112753","article-title":"T follicular helper and T follicular regulatory cells in colorectal cancer: a complex interplay","volume":"480","author":"Hetta","year":"2020","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.jtbi.2026.112493_bib0041","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.coi.2021.03.016","article-title":"Modulation of the tumor micro-environment by CD8+ T cell-derived cytokines","volume":"69","author":"Hoekstra","year":"2021","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.jtbi.2026.112493_bib0042","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/90950","article-title":"Differential regulation of antiviral T-cell immunity results in stable CD8+ but declining CD4+ T-cell memory","volume":"7","author":"Homann","year":"2001","journal-title":"Nat. Med."},{"key":"10.1016\/j.jtbi.2026.112493_bib0043","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0009-9236(97)90065-5","article-title":"Pharmacodynamics of subcutaneous recombinant human interleukin-10 in healthy volunteers","volume":"62","author":"Huhn","year":"1997","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jtbi.2026.112493_bib0044","doi-asserted-by":"crossref","first-page":"896","DOI":"10.4049\/jimmunol.177.2.896","article-title":"Suppression of antitumor immunity by IL-10 and TGF-\u03b2-Producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells","volume":"177","author":"Jarnicki","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.jtbi.2026.112493_bib0045","doi-asserted-by":"crossref","first-page":"5017","DOI":"10.4049\/jimmunol.165.9.5017","article-title":"Two distinct stages in the transition from naive CD4 T cells to effectors, early antigen-dependent and late cytokine-driven expansion and differentiation","volume":"165","author":"Jelley-Gibbs","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.jtbi.2026.112493_bib0046","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/87720","article-title":"Memory CD8+ T cell differentiation: initial antigen encounter triggers a developmental program in na\u00efve cells","volume":"2","author":"Kaech","year":"2001","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jtbi.2026.112493_bib0047","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nri778","article-title":"Effector and memory T-cell differentiation: implications for vaccine development","volume":"2","author":"Kaech","year":"2002","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jtbi.2026.112493_bib0048","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1182\/blood.V100.5.1734.h81702001734_1734_1741","article-title":"Developmental kinetics and lifespan of dendritic cells in mouse lymphoid organs","volume":"100","author":"Kamath","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jtbi.2026.112493_bib0049","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1026954","article-title":"Major pathways involved in macrophage polarization in cancer","volume":"13","author":"Kerneur","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jtbi.2026.112493_bib0050","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms7301","article-title":"Real-time tracking of cell cycle progression during CD8+ effector and memory T-cell differentiation","volume":"6","author":"Kinjyo","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jtbi.2026.112493_bib0051","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.3390\/jcm9123947","article-title":"Data driven mathematical model of colon cancer progression","volume":"9","author":"Kirshtein","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.jtbi.2026.112493_bib0052","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.584680","article-title":"Mature dendritic cells may promote high-avidity tuning of vaccine t cell responses","volume":"11","author":"Kumbhari","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jtbi.2026.112493_bib0053","doi-asserted-by":"crossref","DOI":"10.1016\/j.mbs.2021.108556","article-title":"A minimal model of T cell avidity may identify subtherapeutic vaccine schedules","volume":"334","author":"Kumbhari","year":"2021","journal-title":"Math. Biosci."},{"key":"10.1016\/j.jtbi.2026.112493_bib0054","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0178479","article-title":"Combination therapy of cancer with cancer vaccine and immune checkpoint inhibitors: a mathematical model","volume":"12","author":"Lai","year":"2017","journal-title":"PLOS ONE"},{"key":"10.1016\/j.jtbi.2026.112493_bib0055","doi-asserted-by":"crossref","DOI":"10.1186\/s12918-019-0706-y","article-title":"How to schedule VEGF and PD-1 inhibitors in combination cancer therapy?","volume":"13","author":"Lai","year":"2019","journal-title":"BMC Syst. Biol."},{"key":"10.1016\/j.jtbi.2026.112493_bib0056","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1002\/cpt.2129","article-title":"Experimental medicine study to measure immune checkpoint receptors PD-1 and GITR turnover rates in Vivo in humans","volume":"109","author":"Lassman","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jtbi.2026.112493_bib0057","doi-asserted-by":"crossref","first-page":"632","DOI":"10.3390\/vaccines8040632","article-title":"Cancer immunotherapy dosing: a pharmacokinetic\/pharmacodynamic perspective","volume":"8","author":"Le Louedec","year":"2020","journal-title":"Vaccines"},{"key":"10.1016\/j.jtbi.2026.112493_bib0058","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1615\/ForumImmunDisTher.2015014188","article-title":"Reinvigorating exhausted t cells by blockade of the PD-1 pathway","volume":"6","author":"Lee","year":"2015","journal-title":"Forum Immunopathol. Dis. Ther."},{"key":"10.1016\/j.jtbi.2026.112493_bib0059","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.xphs.2018.10.064","article-title":"Semimechanistically based modeling of pembrolizumab time-varying clearance using 4 longitudinal covariates in patients with non\u2013small cell lung cancer","volume":"108","author":"Li","year":"2019","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jtbi.2026.112493_bib0060","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10928-017-9528-y","article-title":"Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response","volume":"44","author":"Li","year":"2017","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.jtbi.2026.112493_bib0061","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/cpt.2170","article-title":"Pivotal dose of pembrolizumab: a dose-finding strategy for immuno-oncology","volume":"110","author":"Li","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jtbi.2026.112493_bib0062","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtbi.2023.111704","article-title":"IL-27 in combination with anti-PD-1 can be anti-cancer or pro-cancer","volume":"579","author":"Liao","year":"2024","journal-title":"J. Theor. Biol."},{"key":"10.1016\/j.jtbi.2026.112493_bib0063","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-024-02023-w","article-title":"Regulatory mechanisms of PD-1\/PD-L1 in cancers","volume":"23","author":"Lin","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.jtbi.2026.112493_bib0064","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/2159-8290.CD-14-0863","article-title":"The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints","volume":"5","author":"Llosa","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.jtbi.2026.112493_bib0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0165782","article-title":"Inflammatory bowel disease: how effective is TNF-\u03b1 suppression?","volume":"11","author":"Lo","year":"2016","journal-title":"PLOS ONE"},{"key":"10.1016\/j.jtbi.2026.112493_bib0066","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.4049\/jimmunol.135.4.2865","article-title":"In vivo administration of purified human interleukin 2. II. half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2","volume":"135","author":"Lotze","year":"1985","journal-title":"J. Immunol."},{"key":"10.1016\/j.jtbi.2026.112493_bib0067","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.01061","article-title":"Potentiation of natural killer cells for cancer immunotherapy: a review of literature","volume":"8","author":"Lowry","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jtbi.2026.112493_bib0068","article-title":"A novel recombinant slow-release TNF \u03b1-derived peptide effectively inhibits tumor growth and angiogensis","volume":"5","author":"Ma","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jtbi.2026.112493_bib0069","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.csbj.2018.11.004","article-title":"Fates of CD8+ t cells in tumor microenvironment","volume":"17","author":"Maimela","year":"2019","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.1016\/j.jtbi.2026.112493_bib0070","doi-asserted-by":"crossref","DOI":"10.1186\/s13058-015-0638-4","article-title":"An ecological measure of immune-cancer colocalization as a prognostic factor for breast cancer","volume":"17","author":"Maley","year":"2015","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.jtbi.2026.112493_bib0071","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jtbi.2026.112493_bib0072","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1128\/JVI.01459-06","article-title":"Quantitating the magnitude of the lymphocytic choriomeningitis virus-specific CD8 T-Cell response: it is even bigger than we thought","volume":"81","author":"Masopust","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.jtbi.2026.112493_bib0073","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1146\/annurev-immunol-041015-055318","article-title":"CD8 T cell exhaustion during chronic viral infection and cancer","volume":"37","author":"McLane","year":"2019","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.jtbi.2026.112493_bib0074","unstructured":"Merck, 2021. KEYTRUDA (pembrolizumab) injection Label. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/125514s096lbl.pdf."},{"key":"10.1016\/j.jtbi.2026.112493_bib0075","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1615\/CritRevImmunol.v32.i6.10","article-title":"M1 and M2 macrophages: oracles of health and disease","volume":"32","author":"Mills","year":"2012","journal-title":"Crit. Rev. Immunol."},{"key":"10.1016\/j.jtbi.2026.112493_bib0076","doi-asserted-by":"crossref","DOI":"10.3748\/wjg.v20.i30.10316","article-title":"FOLFOX\/FOLFIRI Pharmacogenetics: the call for a personalized approach in colorectal cancer therapy","volume":"20","author":"Mohelnikova-Duchonova","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.jtbi.2026.112493_bib0077","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.3390\/cancers15041022","article-title":"Challenges and therapeutic opportunities in the dMMR\/MSI-H colorectal cancer landscape","volume":"15","author":"Mulet-Margalef","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.jtbi.2026.112493_bib0078","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.00396","article-title":"Review of PD-1\/PD-L1 inhibitors in metastatic dMMR\/MSI-H colorectal cancer","volume":"9","author":"Oliveira","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jtbi.2026.112493_bib0079","first-page":"115","article-title":"Cytokine kinetics in an in vitro whole blood model following an endotoxin challenge","volume":"12","author":"Oliver","year":"1993","journal-title":"Lymphokine Cytokine Res."},{"key":"10.1016\/j.jtbi.2026.112493_bib0080","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2017.76.9901","article-title":"Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair\u2013deficient\/microsatellite instability\u2013high metastatic colorectal cancer","volume":"36","author":"Overman","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jtbi.2026.112493_bib0081","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1084\/jem.20170355","article-title":"The fate and lifespan of human monocyte subsets in steady state and systemic inflammation","volume":"214","author":"Patel","year":"2017","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jtbi.2026.112493_bib0082","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.1158\/1078-0432.CCR-14-2607","article-title":"Phase i study of pembrolizumab (MK-3475; anti\u2013PD-1 monoclonal antibody) in patients with advanced solid tumors","volume":"21","author":"Patnaik","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jtbi.2026.112493_bib0083","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2116260119","article-title":"Heritable changes in division speed accompany the diversification of single T cell fate","volume":"119","author":"Plambeck","year":"2022","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jtbi.2026.112493_bib0084","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.cyto.2014.09.011","article-title":"T cell subsets and their signature cytokines in autoimmune and inflammatory diseases","volume":"74","author":"Raphael","year":"2015","journal-title":"Cytokine"},{"key":"10.1016\/j.jtbi.2026.112493_bib0085","doi-asserted-by":"crossref","first-page":"89","DOI":"10.5114\/pg.2018.81072","article-title":"Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors","volume":"14","author":"Rawla","year":"2019","journal-title":"Gastroenterol. Rev."},{"key":"10.1016\/j.jtbi.2026.112493_bib0086","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jtbi.2026.112493_bib0087","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/modpathol.2016.227","article-title":"Tumor size, tumor location, and antitumor inflammatory response are associated with lymph node size in colorectal cancer patients","volume":"30","author":"R\u00f6ssler","year":"2017","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.jtbi.2026.112493_bib0088","doi-asserted-by":"crossref","first-page":"4910","DOI":"10.4049\/jimmunol.165.9.4910","article-title":"Anatomical origin of dendritic cells determines their life span in peripheral lymph nodes","volume":"165","author":"Ruedl","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.jtbi.2026.112493_bib0089","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s10928-023-09850-2","article-title":"A comprehensive regulatory and industry review of modeling and simulation practices in oncology clinical drug development","volume":"50","author":"Ruiz-Garcia","year":"2023","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.jtbi.2026.112493_bib0090","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s10928-015-9413-5","article-title":"The impact of composite AUC estimates on the prediction of systemic exposure in toxicology experiments","volume":"42","author":"Sahota","year":"2015","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.jtbi.2026.112493_bib0091","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.canlet.2019.05.003","article-title":"Treg-mediated acquired resistance to immune checkpoint inhibitors","volume":"457","author":"Saleh","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/j.jtbi.2026.112493_bib0092","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0167-9473(97)00043-1","article-title":"An alternative way to compute fourier amplitude sensitivity test (FAST)","volume":"26","author":"Saltelli","year":"1998","journal-title":"Comput. Stat. Amp Data Anal."},{"key":"10.1016\/j.jtbi.2026.112493_bib0093","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1080\/00401706.1999.10485594","article-title":"A quantitative model-independent method for global sensitivity analysis of model output","volume":"41","author":"Saltelli","year":"1999","journal-title":"Technometrics"},{"key":"10.1016\/j.jtbi.2026.112493_bib0094","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.2217\/fon-2017-0696","article-title":"Nivolumab in the treatment of microsatellite instability high metastatic colorectal cancer","volume":"14","author":"Sarshekeh","year":"2018","journal-title":"Future Oncol."},{"key":"10.1016\/j.jtbi.2026.112493_bib0095","article-title":"T cell receptor (TCR) signaling in health and disease","volume":"6","author":"Shah","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jtbi.2026.112493_bib0096","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00253","article-title":"Outcomes of chemotherapy for microsatellite instable\u2013high metastatic colorectal cancers","author":"Shulman","year":"2018","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.jtbi.2026.112493_bib0097","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0252620","article-title":"TGF-\u03b2 Inhibition can overcome cancer primary resistance to PD-1 blockade: a mathematical model","volume":"16","author":"Siewe","year":"2021","journal-title":"PLOS ONE"},{"key":"10.1016\/j.jtbi.2026.112493_bib0098","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtbi.2022.111297","article-title":"Cancer therapy with immune checkpoint inhibitor and CSF-1 blockade: a mathematical model","volume":"556","author":"Siewe","year":"2023","journal-title":"J. Theor. Biol."},{"key":"10.1016\/j.jtbi.2026.112493_bib0099","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1093\/jnci\/djr153","article-title":"DNA Mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy","volume":"103","author":"Sinicrope","year":"2011","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"10.1016\/j.jtbi.2026.112493_bib0100","first-page":"407","article-title":"Sensitivity analysis for non-linear mathematical models","volume":"1","author":"Sobol\u2019","year":"1993","journal-title":"Math. Modeling Comput. Exp."},{"key":"10.1016\/j.jtbi.2026.112493_bib0101","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1084\/jem.20082553","article-title":"Self\u2013class I MHC molecules support survival of naive CD8 T cells, but depress their functional sensitivity through regulation of CD8 expression levels","volume":"206","author":"Takada","year":"2009","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jtbi.2026.112493_bib0102","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/318481","article-title":"TGF-\u03b2: An important mediator of allergic disease and a molecule with dual activity in cancer development","volume":"2014","author":"Tirado-Rodriguez","year":"2014","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.jtbi.2026.112493_bib0103","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti\u2013PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jtbi.2026.112493_bib0104","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.immuni.2016.01.013","article-title":"Interleukin-35 limits anti-tumor immunity","volume":"44","author":"Turnis","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.jtbi.2026.112493_bib0105","doi-asserted-by":"crossref","first-page":"5322","DOI":"10.1158\/1078-0432.CCR-14-0332","article-title":"Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies","volume":"20","author":"Venderbosch","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jtbi.2026.112493_bib0106","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01462","article-title":"The metabolic signature of macrophage responses","volume":"10","author":"Viola","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jtbi.2026.112493_bib0107","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/ni1582","article-title":"Functions of natural killer cells","volume":"9","author":"Vivier","year":"2008","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jtbi.2026.112493_bib0108","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1172\/JCI28941","article-title":"Human CD4+ CD25hi foxp3+ regulatory T cells are derived by rapid turnover of memory populations in vivo","volume":"116","author":"Vukmanovic-Stejic","year":"2006","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.jtbi.2026.112493_bib0109","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1158\/2326-6066.CIR-22-0041","article-title":"Treg-dominant tumor microenvironment is responsible for hyperprogressive disease after PD-1\u202fblockade therapy","volume":"10","author":"Wakiyama","year":"2022","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.jtbi.2026.112493_bib0110","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/PPO.0000000000000296","article-title":"Toxicities associated with PD-1\/PD-L1 blockade","volume":"24","author":"Wang","year":"2018","journal-title":"Cancer J."},{"key":"10.1016\/j.jtbi.2026.112493_bib0111","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008026","article-title":"Tumor-draining lymph nodes: opportunities, challenges, and future directions in colorectal cancer immunotherapy","volume":"12","author":"Wang","year":"2024","journal-title":"J. ImmunoTher. Cancer"},{"key":"10.1016\/j.jtbi.2026.112493_bib0112","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-020-01238-x","article-title":"Natural killer cells in cancer biology and therapy","volume":"19","author":"Wu","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.jtbi.2026.112493_bib0113","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.canlet.2016.01.043","article-title":"Tumor microenvironment and therapeutic response","volume":"387","author":"Wu","year":"2017","journal-title":"Cancer Lett."},{"key":"10.1016\/j.jtbi.2026.112493_bib0114","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.immuni.2014.01.006","article-title":"Transcriptome-based network analysis reveals a spectrum model of human macrophage activation","volume":"40","author":"Xue","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.jtbi.2026.112493_bib0115","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.biopha.2018.11.105","article-title":"PD-1\/ PD-L1 blockade as a novel treatment for colorectal cancer","volume":"110","author":"Yaghoubi","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.jtbi.2026.112493_bib0116","doi-asserted-by":"crossref","first-page":"11621","DOI":"10.1074\/jbc.M113.449942","article-title":"Real-time kinetics of high-mobility group box 1 (HMGB1) oxidation in extracellular fluids studied by in situ Protein NMR spectroscopy","volume":"288","author":"Zandarashvili","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jtbi.2026.112493_bib0117","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.3390\/cancers13112801","article-title":"Engineering calreticulin-targeting monobodies to detect immunogenic cell death in cancer chemotherapy","volume":"13","author":"Zhang","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.jtbi.2026.112493_bib0118","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","article-title":"The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications","volume":"17","author":"Zhang","year":"2020","journal-title":"Cell. Mol. Immunol."}],"container-title":["Journal of Theoretical Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022519326001189?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022519326001189?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T19:42:34Z","timestamp":1783194154000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022519326001189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":118,"alternative-id":["S0022519326001189"],"URL":"https:\/\/doi.org\/10.1016\/j.jtbi.2026.112493","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2025.05.23.655752","asserted-by":"object"}]},"ISSN":["0022-5193"],"issn-type":[{"value":"0022-5193","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimisation of pembrolizumab therapy for de novo metastatic MSI-H\/dMMR colorectal cancer using data-driven delay integro-differential equations","name":"articletitle","label":"Article Title"},{"value":"Journal of Theoretical Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtbi.2026.112493","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"112493"}}